客户使用产品发表文献 2 篇

产品文档

Quality Control & SDS

View current batch:

Purity: >99.50%

实验参考方法

Cell experiment [1]:
Cell lines	Tendon cells
Preparation Method	Cells were first seeded into 24-well flat-bottomed culture plates. Celecoxib was then added to the culture dish at dosages of 0, 0.8, 2.0, 4.0, and 8.0µg/mL. Then 24h after Celecoxib was added to cells, cells were observed under microscope and then MTT assay was performed.
Reaction Conditions	0.8, 2.0, 4.0, 8.0µg/mL; 24h
Applications	Celecoxib dose-dependently inhibited tendon cell viability and migration, but no cell necrosis or changes in cell morphology were observed.
Animal experiment [2]:
Animal models	Female BALB/c nude mice
Preparation Method	Mice were randomly divided into the following five treatment groups: control; mice were injected with PGE2 (1mg/kg); mice were injected with PGE2 (1mg/kg) and Celecoxib (100mg/kg); mice received pneumonectomy; mice received pneumonectomy and Celecoxib (100mg/kg). A549 cells were prepared as a suspension of 10⁶cells in 150µL saline and injected using a 29-gauge needle into the lateral tail vein under sterile conditions. Celecoxib (100mg/kg) was administered orally starting from the day before tumor cell injection until the mice were sacrificed. After the mice were sacrificed, the lungs were flushed with 5% picric acid solution. Lung metastasis was determined by counting the total number of metastatic nodules in each lung.
Dosage form	100mg/kg; p.o.
Applications	The metastasis of A549 cells in mice receiving unilateral pneumonec tomy was more than that in control mice, and treatment with Celecoxib inhibited this increase in metastases. The mean level of plasma PGE2 in mice receive ing unilateral pneumonectomy increased, and treatment with Celecoxib significantly inhibited the increase in PGE2 plasma level.
References: [1]Tsai W C, Hsu C C, Chou S W, et al. Effects of celecoxib on migration, proliferation and collagen expression of tendon cells[J]. Connective tissue research, 2007, 48(1): 46-51. [2]Zhang S, Da L, Yang X, et al. Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway[J]. Toxicology letters, 2014, 225(2): 201-207.

产品描述

Celecoxib is a highly selective cyclooxygenase-2 (COX-2) inhibitor with an IC₅₀ value of 40nM^[1]. Celecoxib is a selective nonsteroidal anti-inflammatory drug (NSAID) commonly used to treat acute pain, osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis and ankylosing spondylitis (AS)^[2]. Celecoxib has strong anti-tumor activity and can prevent and treat a variety of cancers such as pancreatic cancer, breast cancer, ovarian cancer, and non-small cell lung cancer^[3]. Celecoxib can prevent the occurrence of colorectal adenomatous polyps^[4].

In vitro, Celecoxib (0.8, 2.0, 4.0, 8.0µg/mL) treated tenocytes for 24h dose-dependently inhibited cell viability and migration, but did not change cell morphology or cause cell necrosis^[5]. Celecoxib (1-100μM) treated human osteoblasts for 24h, inhibited cell proliferation in a dose-dependent manner and caused an increase in intracellular Ca²⁺ concentration^[6].

In vivo, Celecoxib (100mg/kg) was orally administered to mice with lung cancer model and unilateral lung resection, inhibiting lung cancer metastasis and the increase in plasma PGE2 levels^[7]. Celecoxib (10, 20mg/kg) was orally administered to rats with gastric cancer model, significantly reducing the incidence and growth of gastric cancer in rats^[8].

References:
[1] Cao H, Yu R, Choi Y, et al. Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation[J]. Pharmacological research, 2010, 61(6): 519-524.
[2] Frampton J E, Keating G M. Celecoxib: a review of its use in the management of arthritis and acute pain[J]. Drugs, 2007, 67: 2433-2474.
[3] Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer[J]. Cancer letters, 2013, 332(2): 313-324.
[4] Arber N, Eagle C J, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps[J]. New England Journal of Medicine, 2006, 355(9): 885-895.
[5] Tsai W C, Hsu C C, Chou S W, et al. Effects of celecoxib on migration, proliferation and collagen expression of tendon cells[J]. Connective tissue research, 2007, 48(1): 46-51.
[6] Wang J L, Lin K L, Chen J S, et al. Effect of celecoxib on Ca2+ movement and cell proliferation in human osteoblasts[J]. Biochemical pharmacology, 2004, 67(6): 1123-1130.
[7] Zhang S, Da L, Yang X, et al. Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway[J]. Toxicology letters, 2014, 225(2): 201-207.
[8] Hu P J, Yu J, Zeng Z R, et al. Chemoprevention of gastric cancer by celecoxib in rats[J]. Gut, 2004, 53(2): 195-200.

Celecoxib是一种高度选择性的环氧合酶-2（COX-2）抑制剂，IC₅₀值为40nM^[¹^]。Celecoxib是一种选择性非甾体抗炎药（NSAID），常用于治疗急性疼痛、骨关节炎（OA）、类风湿性关节炎（RA）、幼年类风湿性关节炎和强直性脊柱炎（AS）等^[²^]。Celecoxib 具有强大的抗肿瘤活性，能够预防和治疗胰腺癌、乳腺癌、卵巢癌、非小细胞肺癌等多种癌症^[³^]。Celecoxib能够预防结直肠腺瘤性息肉的发生^[⁴^]。

在体外，Celecoxib（0.8, 2.0, 4.0, 8.0µg/mL）处理肌腱细胞24h，剂量依赖性地抑制了细胞活力和迁移，但不改变细胞形态或造成细胞坏死^[⁵^]。Celecoxib（1-100μM）处理人成骨细胞24h，剂量依赖性地抑制了细胞增殖，引起了细胞内Ca²⁺浓度的增加^[⁶^]。

在体内，Celecoxib（100mg/kg）通过口服治疗肺癌模型并做了单侧肺切除手术的小鼠，抑制了肺癌转移，抑制了血浆PGE2水平的升高^[⁷^]。Celecoxib（10、20mg/kg）通过口服治疗胃癌模型大鼠，显著降低了大鼠胃癌的发病率和生长^[⁸^]。

Chemical Properties

Cas No.	169590-42-5	SDF
别名	塞来昔布; SC 58635
化学名	4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
Canonical SMILES	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
分子式	C₁₇H₁₄F₃N₃O₂S	分子量	381.37
溶解度	≥ 19.1mg/mL in DMSO	储存条件	Store at -20°C
General tips	请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。
Shipping Condition	评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。

溶解性数据

制备储备液
		1 mg	5 mg	10 mg
	1 mM	2.6221 mL	13.1106 mL	26.2213 mL
	5 mM	0.5244 mL	2.6221 mL	5.2443 mL
	10 mM	0.2622 mL	1.3111 mL	2.6221 mL

摩尔浓度计算器
稀释计算器
分子量计算器

计算

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

g

每只动物给药体积

ul

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % saline

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系GLPBIO）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。

Celecoxib

Customer Reviews

B1

客户使用产品发表文献 2 篇

产品文档

Quality Control & SDS

实验参考方法

产品描述

Chemical Properties

溶解性数据

摩尔浓度计算器

稀释计算器

分子量计算器

动物体内配方计算器 (澄清溶液)

相关产品